Displaying 133 - 144 of 149
Viral Hepatitis
5

Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021

View
Viral Hepatitis
5

Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021

View
Viral Hepatitis
5

Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021

View
Viral Hepatitis
5

Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Immune-Mediated and Cholestatic Diseases
1

Albireo: Challenges in the Management of Patients with Cholestatic Liver Diseases - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Displaying 133 - 144 of 149